238 related articles for article (PubMed ID: 34381017)
1. Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells.
Wang Y; Chen Q; Wu D; Chen Q; Gong G; He L; Wu X
Cell Death Dis; 2021 Aug; 12(8):786. PubMed ID: 34381017
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
Stecklein SR; Kumaraswamy E; Behbod F; Wang W; Chaguturu V; Harlan-Williams LM; Jensen RA
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13650-5. PubMed ID: 22869732
[TBL] [Abstract][Full Text] [Related]
4. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.
Mo Q; Zhang Y; Jin X; Gao Y; Wu Y; Hao X; Gao Q; Chen P
Tumour Biol; 2016 Nov; 37(11):14745-14755. PubMed ID: 27629142
[TBL] [Abstract][Full Text] [Related]
5. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma.
Yan W; Xiao J; Liu T; Huang W; Yang X; Wu Z; Huang Q; Qian M
Tumour Biol; 2013 Jun; 34(3):1391-7. PubMed ID: 23456764
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
Huntoon CJ; Nye MD; Geng L; Peterson KL; Flatten KS; Haluska P; Kaufmann SH; Karnitz LM
Cancer Res; 2010 Nov; 70(21):8642-50. PubMed ID: 20841485
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
Li Y; Zhang T; Schwartz SJ; Sun D
Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
9. Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
Wang Y; Jiang J; He L; Gong G; Wu X
Gynecol Oncol; 2019 Jan; 152(1):166-176. PubMed ID: 30384980
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
11. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
12. Hsp90α regulates ATM and NBN functions in sensing and repair of DNA double-strand breaks.
Pennisi R; Antoccia A; Leone S; Ascenzi P; di Masi A
FEBS J; 2017 Aug; 284(15):2378-2395. PubMed ID: 28631426
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hsp90 compromises the DNA damage response to radiation.
Dote H; Burgan WE; Camphausen K; Tofilon PJ
Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
[TBL] [Abstract][Full Text] [Related]
15. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
16. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.
Zhou JW; Tang JJ; Sun W; Wang H
Mol Med; 2019 Mar; 25(1):11. PubMed ID: 30925862
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y
Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180
[TBL] [Abstract][Full Text] [Related]
18. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
